Alogliptin vs. Placebo and Heart Failure Outcomes: Reassuring Results, but Uncertainties Remain | Journal Scan

Study Questions:

In the EXAMINE trial (which demonstrated the noninferiority of the dipeptidyl peptidase 4 [DPP-4] inhibitor alogliptin to placebo on major adverse cardiac event [MACE] rates in patients with type 2 diabetes and recent acute coronary syndrome), did alogliptin increase the risk of heart failure outcomes?